These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 12789698)

  • 1. Life-cycle management: a long-term challenge.
    Newman C
    Med Device Technol; 2003 Apr; 14(3):32-3. PubMed ID: 12789698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical electronics: buy now.
    European Coordination Committee of Radiological and Electromedical Manufacturers
    Med Device Technol; 2003 Jun; 14(5):37. PubMed ID: 12852124
    [No Abstract]   [Full Text] [Related]  

  • 3. HFMA roundtable. Capital planning: how strategic is your organization?
    Frederick C; Lux RH; Morris J; O'Connell B; Wiest J; Fincher N
    Healthc Financ Manage; 2006 Jul; 60(7):suppl 1-4 following 32. PubMed ID: 16869319
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessing new technology: how are other hospitals facing the challenge?
    Rosenstein AH; O'Daniel M; Geoghan K
    Healthc Financ Manage; 2003 Oct; 57(10):70-4. PubMed ID: 14560583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health technology assessment from a Canadian device industry perspective.
    Ferrusi IL; Ames D; Lim ME; Goeree R
    J Am Coll Radiol; 2009 May; 6(5):353-9. PubMed ID: 19394576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balancing clinical priorities in an era of diminishing resources.
    Berkowitz DA; Youngblood W
    Hosp Mater Manage Q; 1993 Aug; 15(1):42-53. PubMed ID: 10127555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physician assessment of office-based technologies.
    Magel JS
    Top Health Care Financ; 1992; 18(3):80-8. PubMed ID: 1585360
    [No Abstract]   [Full Text] [Related]  

  • 8. Human factors engineering: a tool for medical device evaluation in hospital procurement decision-making.
    Ginsburg G
    J Biomed Inform; 2005 Jun; 38(3):213-9. PubMed ID: 15896694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy assessment criteria based on risk and cost.
    MacIntyre NR
    Respir Care; 1995 Sep; 40(9):968-70. PubMed ID: 10152241
    [No Abstract]   [Full Text] [Related]  

  • 10. Reducing technology costs and risks in a managed care environment.
    Halverson K
    Manag Care Q; 1997; 5(1):30-2. PubMed ID: 10164647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expected value of information and decision making in HTA.
    Eckermann S; Willan AR
    Health Econ; 2007 Feb; 16(2):195-209. PubMed ID: 16981193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What price progress? Technology assessment teams field requests--and politics.
    Taylor KS
    Health Facil Manage; 1995 Feb; 8(2):20, 22-4. PubMed ID: 10139798
    [No Abstract]   [Full Text] [Related]  

  • 13. Embedding quality improvement and patient safety: the UCLA value analysis experience.
    Gambone JC; Broder MS
    Best Pract Res Clin Obstet Gynaecol; 2007 Aug; 21(4):581-92. PubMed ID: 17400513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marketplace. Assessing medical innovations: how health plans pick what technology to cover.
    Moskowitz DB
    Faulkner Grays Med Health; 1997 May; 51(21):suppl 2 p.. PubMed ID: 10167124
    [No Abstract]   [Full Text] [Related]  

  • 15. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
    von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective value-based assessment of new health care technologies and practices.
    Girod CS; Axene DV
    Manag Care; 2000 Aug; 9(8):38-40, 43-7. PubMed ID: 11186514
    [No Abstract]   [Full Text] [Related]  

  • 17. The patent gamble: strategic insights for playing the worldwide patent game.
    Barrett WA
    Nat Biotechnol; 2003 Dec; 21(12):1515-7. PubMed ID: 14647335
    [No Abstract]   [Full Text] [Related]  

  • 18. The supply chain and clinical quality.
    Runy LA
    Mater Manag Health Care; 2005 May; 14(5):21-6. PubMed ID: 16047455
    [No Abstract]   [Full Text] [Related]  

  • 19. Proper device analysis requires adequate preparation. Involving end users helps ensure ownership, buy-in and acceptance.
    Cusick C
    Mater Manag Health Care; 2007 Jul; 16(7):38-41. PubMed ID: 17955934
    [No Abstract]   [Full Text] [Related]  

  • 20. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.